ID
16017
Description
Documentation part: Basic Subject Data & Eligibility A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo. ClinicalTrials.gov Identifier: NCT00133874 Other Study ID Numbers: TOC100224 Responsible Party: GlaxoSmithKline
Keywords
Versions (1)
- 6/26/16 6/26/16 -
Uploaded on
June 26, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Basic Subject Data & Eligibility Topical SB-275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
Basic Subject Data & Eligibility Topical SB-275833 Ointment 1% For The Treatment Of Impetigo NCT00133874
Description
Inform enrolment (ENROL)
Description
Date of visit
Description
Subject Identification
Description
Eligibility Question